BIO vs CPRX · rev $651.0M vs P/E 18, rev $491.7M
BIO (BIO) versus Catalyst Pharmaceuticals Inc (CPRX) — a side-by-side from cached financials, not a winner call.
BIO (BIO) common stock.
Catalyst Pharmaceuticals Inc (CPRX) is a biotechnology company listed on NASDAQ.
Latest reported BIO revenue for 2026-06-30 was $651.0M. Net income was $371.4M. Revenue was up 9.9% from 2026-03-31 to 2026-06-30. BIO currently screens at market cap $0.
Latest reported CPRX revenue for 2024-12-31 was $491.7M. Net income was $163.9M. Revenue was up 23.5% from 2023-12-31 to 2024-12-31. CPRX currently screens at market cap $3.84B and trailing P/E 18.2.
BIO currently screens at market cap $0. CPRX currently screens at market cap $3.84B and trailing P/E 18.2.
Not investment advice. Open the BIO and CPRX stock pages for the full models.
Not investment advice.